Back to top
more

AxoGen (AXGN)

(Delayed Data from NSDQ)

$5.75 USD

5.75
165,623

-0.23 (-3.85%)

Updated May 10, 2024 04:00 PM ET

After-Market: $5.76 +0.01 (0.17%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 250)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Here's Why "Trend" Investors Would Love Betting on AxoGen (AXGN)

If you are looking for stocks that are well positioned to maintain their recent uptrend, AxoGen (AXGN) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

AxoGen (AXGN) Reports Q3 Loss, Tops Revenue Estimates

AxoGen (AXGN) delivered earnings and revenue surprises of 93.33% and 2.38%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Si-Bone (SIBN) Reports Q3 Loss, Tops Revenue Estimates

Si-Bone (SIBN) delivered earnings and revenue surprises of 8.89% and 0.29%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Orthofix (OFIX) Q3 Earnings and Revenues Surpass Estimates

Orthofix (OFIX) delivered earnings and revenue surprises of 550% and 2.70%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

AxoGen (AXGN) Upgraded to Buy: Here's What You Should Know

AxoGen (AXGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Are Medical Stocks Lagging Catalyst Pharmaceuticals (CPRX) This Year?

Here is how Catalyst Pharmaceutical (CPRX) and AxoGen (AXGN) have performed compared to their sector so far this year.

AxoGen (AXGN) Soars 8.6%: Is Further Upside Left in the Stock?

AxoGen (AXGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Wall Street Analysts Think AxoGen (AXGN) Could Surge 89%: Read This Before Placing a Bet

The consensus price target hints at an 89.4% upside potential for AxoGen (AXGN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Are Medical Stocks Lagging Acadia Healthcare (ACHC) This Year?

Here is how Acadia Healthcare (ACHC) and AxoGen (AXGN) have performed compared to their sector so far this year.

AxoGen (AXGN) Reports Q2 Loss, Tops Revenue Estimates

AxoGen (AXGN) delivered earnings and revenue surprises of 60% and 5.04%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

AxoGen (AXGN) Reports Q1 Loss, Tops Revenue Estimates

AxoGen (AXGN) delivered earnings and revenue surprises of -17.65% and 2%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

AxoGen (AXGN) Reports Q4 Loss, Tops Revenue Estimates

AxoGen (AXGN) delivered earnings and revenue surprises of 38.46% and 0.11%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: AxoGen (AXGN) Q4 Earnings Expected to Decline

AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AxoGen (AXGN) Reports Q3 Loss, Misses Revenue Estimates

AxoGen (AXGN) delivered earnings and revenue surprises of 25.00% and -9.95%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

AxoGen (AXGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

AxoGen (AXGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cousins Properties' (CUZ) Heights Union Buyout Fails to Drive Stock

The acquisition of Heights Union is in line with Cousins Properties' (CUZ) efforts to enhance its portfolio quality with trophy assets.

AxoGen (AXGN) Reports Q2 Loss, Tops Revenue Estimates

AxoGen (AXGN) delivered earnings and revenue surprises of 25.00% and 3.96%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

AxoGen (AXGN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AxoGen (AXGN) Stock Jumps 12.5%: Will It Continue to Soar?

AxoGen (AXGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

AxoGen (AXGN) Reports Q1 Loss, Tops Revenue Estimates

AxoGen (AXGN) delivered earnings and revenue surprises of 52.94% and 8.33%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

AxoGen (AXGN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AxoGen (AXGN) Beats Q3 Earnings and Revenue Estimates

AxoGen (AXGN) delivered earnings and revenue surprises of 130.77% and 11.06%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

AxoGen (AXGN) Reports Q2 Loss, Tops Revenue Estimates

AxoGen (AXGN) delivered earnings and revenue surprises of 40.00% and 5.31%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: AxoGen (AXGN) Q2 Earnings Expected to Decline

AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: AxoGen (AXGN) Q1 Earnings Expected to Decline

AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.